Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ALPG


Brief Information

Name:Alkaline phosphatase
Target Synonym:Alkaline Phosphatase
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
ALPP/ALPPL2 mAb - 01 PCC Solid Tumor Endometrial cancer,Ovarian cancer

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Immobilized Human ALPG, His Tag (Cat. No. ALG-H52H9) at 1 μg/mL (100 μL/well) can bind Anti - ALPG / ALPPL2 with a linear range of 0.002-0.125 μg/mL (QC tested).

ALPG MALS images

The purity of Biotinylated Human ALPG Protein, His,Avitag (Cat. No. ALG-H52E1) is more than 90% and the molecular weight of this protein is around 115-135kDa verified by SEC-MALS.

Synonym Name

ALPG,GCAP,ALP-1,ALPPL2,PLAP-like,ALPPL,Alkaline phosphatase, germ cell type


Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Amifostine NSC-296961; YM-08310; S-8744; SAPEP; WR-2721; WR-2721C Approved Medimmune Llc 天地达, 安福定, Ethyol United States Head and Neck Neoplasms; Ovarian Neoplasms Clinigen Inc 1995-12-08 Radiation Injuries; Myelodysplastic-Myeloproliferative Diseases; Salivary Gland Diseases; Mucositis; Lymphoma; Lymphoma, Non-Hodgkin; Lung Neoplasms; Bone Marrow Diseases; Sarcoma; Acute Radiation Syndrome; Breast Neoplasms; Prostatic Neoplasms; Gestational Trophoblastic Disease; Head and Neck Neoplasms; Cytoprotective adjuvant; Nasopharyngeal Neoplasms; Fanconi Anemia; Hodgkin Disease; Myelodysplastic Syndromes; Neutropenia; Carcinoma; Peripheral Nervous System Diseases; Trigeminal Neuralgia; Solid tumours; Ovarian Neoplasms; Drug-Related Side Effects and Adverse Reactions Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ALXN-1850 ALXN-1850 Phase 3 Clinical Alexion Pharmaceuticals Inc Hypophosphatasia Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message